氨甲环酸作为催产素预防的辅助药物，用于预防择期剖宫产妇女产后出血：单中心双盲随机对照试验

Obstetric Anesthesia Digest Pub Date : 2024-05-24 DOI:10.1097/01.aoa.0001016020.37304.ff

S.H. Lee, M.E. Kwek, S. Tagore, A. Wright, C.W. Ku, A. Teong, A. Tan, S.W.C. Lim, D. Yen, C. Ang, R. Sultana, C.H.F. Lim, D. Mathur, M. Mathur

{"title":"氨甲环酸作为催产素预防的辅助药物，用于预防择期剖宫产妇女产后出血：单中心双盲随机对照试验","authors":"S.H. Lee, M.E. Kwek, S. Tagore, A. Wright, C.W. Ku, A. Teong, A. Tan, S.W.C. Lim, D. Yen, C. Ang, R. Sultana, C.H.F. Lim, D. Mathur, M. Mathur","doi":"10.1097/01.aoa.0001016020.37304.ff","DOIUrl":null,"url":null,"abstract":"(BJOG. 2023;130(9):1007–1015)\n Postpartum hemorrhage (PPH) is the main cause of maternal morbidity and mortality worldwide. The World Health Organization (WHO) recommends administration of uterotonics including oxytocin to prevent PPH, but uterotonics alone may not fully prevent PPH from other causes. The World Maternal Antifibrinolytic Trial (WOMAN Trial) reported that tranexamic acid (TXA) reduced PPH-related mortality in PPH cases, and as a result the WHO has included the administration of TXA into their recommendations for PPH treatment. There is speculation about the potential role of prophylactic TXA in preventing PPH.","PeriodicalId":19432,"journal":{"name":"Obstetric Anesthesia Digest","volume":"3 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tranexamic Acid, as an Adjunct to Oxytocin Prophylaxis, in the Prevention of Postpartum Hemorrhage in Women Undergoing Elective Cesarean Section: A Single-Center Double-Blind Randomized Controlled Trial\",\"authors\":\"S.H. Lee, M.E. Kwek, S. Tagore, A. Wright, C.W. Ku, A. Teong, A. Tan, S.W.C. Lim, D. Yen, C. Ang, R. Sultana, C.H.F. Lim, D. Mathur, M. Mathur\",\"doi\":\"10.1097/01.aoa.0001016020.37304.ff\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"(BJOG. 2023;130(9):1007–1015)\\n Postpartum hemorrhage (PPH) is the main cause of maternal morbidity and mortality worldwide. The World Health Organization (WHO) recommends administration of uterotonics including oxytocin to prevent PPH, but uterotonics alone may not fully prevent PPH from other causes. The World Maternal Antifibrinolytic Trial (WOMAN Trial) reported that tranexamic acid (TXA) reduced PPH-related mortality in PPH cases, and as a result the WHO has included the administration of TXA into their recommendations for PPH treatment. There is speculation about the potential role of prophylactic TXA in preventing PPH.\",\"PeriodicalId\":19432,\"journal\":{\"name\":\"Obstetric Anesthesia Digest\",\"volume\":\"3 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetric Anesthesia Digest\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.aoa.0001016020.37304.ff\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetric Anesthesia Digest","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.aoa.0001016020.37304.ff","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

(BJOG.产后出血（PPH）是全球孕产妇发病和死亡的主要原因。世界卫生组织（WHO）建议使用包括催产素在内的子宫收缩剂来预防 PPH，但仅靠子宫收缩剂可能无法完全预防其他原因引起的 PPH。世界产妇抗纤维蛋白溶解试验（WOMAN 试验）报告称，氨甲环酸（TXA）可降低 PPH 病例中与 PPH 相关的死亡率，因此世界卫生组织已将氨甲环酸纳入 PPH 治疗建议中。有人猜测预防性氨甲环酸在预防 PPH 方面可能发挥的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Tranexamic Acid, as an Adjunct to Oxytocin Prophylaxis, in the Prevention of Postpartum Hemorrhage in Women Undergoing Elective Cesarean Section: A Single-Center Double-Blind Randomized Controlled Trial

(BJOG. 2023;130(9):1007–1015) Postpartum hemorrhage (PPH) is the main cause of maternal morbidity and mortality worldwide. The World Health Organization (WHO) recommends administration of uterotonics including oxytocin to prevent PPH, but uterotonics alone may not fully prevent PPH from other causes. The World Maternal Antifibrinolytic Trial (WOMAN Trial) reported that tranexamic acid (TXA) reduced PPH-related mortality in PPH cases, and as a result the WHO has included the administration of TXA into their recommendations for PPH treatment. There is speculation about the potential role of prophylactic TXA in preventing PPH.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Obstetric Anesthesia Digest

自引率

0.00%

发文量